JP2018166506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018166506A5 JP2018166506A5 JP2018089004A JP2018089004A JP2018166506A5 JP 2018166506 A5 JP2018166506 A5 JP 2018166506A5 JP 2018089004 A JP2018089004 A JP 2018089004A JP 2018089004 A JP2018089004 A JP 2018089004A JP 2018166506 A5 JP2018166506 A5 JP 2018166506A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 3
- 108010075254 C-Peptide Proteins 0.000 claims 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000006240 deamidation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588936P | 2012-01-20 | 2012-01-20 | |
| US61/588,936 | 2012-01-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553482A Division JP6352812B6 (ja) | 2012-01-20 | 2013-01-18 | 抗ｃｘｃｒ３抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001152A Division JP2020072715A (ja) | 2012-01-20 | 2020-01-08 | 抗ｃｘｃｒ３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018166506A JP2018166506A (ja) | 2018-11-01 |
| JP2018166506A5 true JP2018166506A5 (enExample) | 2019-01-31 |
| JP6646100B2 JP6646100B2 (ja) | 2020-02-14 |
Family
ID=47633576
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553482A Expired - Fee Related JP6352812B6 (ja) | 2012-01-20 | 2013-01-18 | 抗ｃｘｃｒ３抗体 |
| JP2018089004A Expired - Fee Related JP6646100B2 (ja) | 2012-01-20 | 2018-05-07 | 抗ｃｘｃｒ３抗体 |
| JP2020001152A Pending JP2020072715A (ja) | 2012-01-20 | 2020-01-08 | 抗ｃｘｃｒ３抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553482A Expired - Fee Related JP6352812B6 (ja) | 2012-01-20 | 2013-01-18 | 抗ｃｘｃｒ３抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020001152A Pending JP2020072715A (ja) | 2012-01-20 | 2020-01-08 | 抗ｃｘｃｒ３抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8865870B2 (enExample) |
| EP (1) | EP2804878B1 (enExample) |
| JP (3) | JP6352812B6 (enExample) |
| KR (2) | KR102073034B1 (enExample) |
| CN (1) | CN104507967B (enExample) |
| AR (1) | AR090056A1 (enExample) |
| AU (1) | AU2013209492B2 (enExample) |
| BR (1) | BR112014017814A8 (enExample) |
| CA (1) | CA2862222A1 (enExample) |
| CY (1) | CY1121335T1 (enExample) |
| DK (1) | DK2804878T3 (enExample) |
| ES (1) | ES2698606T3 (enExample) |
| HR (1) | HRP20181874T1 (enExample) |
| HU (1) | HUE041900T2 (enExample) |
| IL (2) | IL233694A0 (enExample) |
| LT (1) | LT2804878T (enExample) |
| MX (1) | MX359854B (enExample) |
| PL (1) | PL2804878T3 (enExample) |
| PT (1) | PT2804878T (enExample) |
| RS (1) | RS58141B1 (enExample) |
| RU (1) | RU2663141C2 (enExample) |
| SG (2) | SG11201406762QA (enExample) |
| SI (1) | SI2804878T1 (enExample) |
| TW (1) | TWI596112B (enExample) |
| UY (1) | UY34582A (enExample) |
| WO (1) | WO2013109974A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| EP3183000A4 (en) | 2014-08-22 | 2018-04-25 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind cxcr3 |
| SG11201803567XA (en) | 2015-10-29 | 2018-05-30 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
| EP3464349A4 (en) * | 2016-05-23 | 2020-08-26 | New York University | COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS |
| JP2020514273A (ja) * | 2016-12-22 | 2020-05-21 | サノフイＳａｎｏｆｉ | 白斑症の処置のための抗ヒトｃｘｃｒ３抗体 |
| KR20190095943A (ko) | 2016-12-22 | 2019-08-16 | 사노피 | 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법 |
| US20180244787A1 (en) | 2016-12-22 | 2018-08-30 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
| EP3752134B1 (en) | 2018-02-16 | 2024-12-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating vitiligo |
| KR102074798B1 (ko) * | 2018-06-15 | 2020-02-07 | 코아스템(주) | 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도 |
| AU2019380503A1 (en) * | 2018-11-14 | 2021-06-03 | Arch Oncology, Inc. | Therapeutic SIRPα antibodies |
| WO2021173753A1 (en) | 2020-02-26 | 2021-09-02 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| BR112022021992A2 (pt) * | 2020-04-30 | 2023-01-03 | Arch Oncology Inc | Método de tratamento de câncer em um sujeito em necessidade do mesmo |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| EP4301784A4 (en) * | 2021-03-02 | 2025-01-01 | NovaRock Biotherapeutics, Ltd. | Antibodies against claudin-6 and uses thereof |
| WO2023019121A2 (en) * | 2021-08-09 | 2023-02-16 | Merck Patent Gmbh | Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250381184A1 (en) | 2022-09-09 | 2025-12-18 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist |
| WO2025185738A1 (zh) * | 2024-03-08 | 2025-09-12 | 演生潮(北京)生物科技有限公司 | 靶向cxcr3的抗原结合蛋白及其应用 |
| WO2026069312A1 (en) | 2024-09-24 | 2026-04-02 | Yeda Research And Development Co. Ltd. | Immune cells expressing an inducible therapeutic agent and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565332A (en) | 1896-08-04 | Toy for making soap-bubbles | ||
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3546807C2 (enExample) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| JP2826272B2 (ja) | 1993-10-26 | 1998-11-18 | タイガースポリマー株式会社 | 中空樹脂成形品の製造装置及び製造方法 |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| ATE360689T1 (de) * | 1996-09-10 | 2007-05-15 | Kocher Theodor Inst | Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung |
| US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2001072334A2 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Methods for treating disease with antibodies to cxcr3 |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| JP2007528711A (ja) * | 2003-06-30 | 2007-10-18 | バイオ−テクノロジー・ジェネラル（イスラエル）リミテッド | 抗体及びその使用 |
| WO2005030793A2 (en) | 2003-09-24 | 2005-04-07 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
| US20070178095A1 (en) * | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| CA2578613A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| JP2009538273A (ja) | 2006-04-14 | 2009-11-05 | トルビオン ファーマシューティカルズ， インコーポレイテッド | 改造されたＦＣエフェクター機能を持つ、免疫グロブリン・ヒンジ領域とＦｃ領域とを備える結合タンパク質 |
| KR20100014869A (ko) * | 2007-02-01 | 2010-02-11 | 테바 바이오파머수티컬스 유에스에이, 아이엔씨. | Ｃｘｃｒ3에 대한 인간화 항체 |
| PE20090993A1 (es) | 2007-08-29 | 2009-07-08 | Sanofi Aventis | Anticuerpos anti-cxcr5 humanizados y derivados de los mismos |
| US20100130476A1 (en) | 2008-11-12 | 2010-05-27 | The Scripps Research Institute | Compounds that induce pancreatic beta-cell expansion |
| WO2010103517A1 (en) * | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| EP2539366B1 (en) * | 2010-02-26 | 2017-11-08 | BioArtic Neuroscience AB | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
-
2013
- 2013-01-18 DK DK13702548.2T patent/DK2804878T3/en active
- 2013-01-18 SI SI201331249T patent/SI2804878T1/sl unknown
- 2013-01-18 PL PL13702548T patent/PL2804878T3/pl unknown
- 2013-01-18 RU RU2014134043A patent/RU2663141C2/ru active
- 2013-01-18 LT LTEP13702548.2T patent/LT2804878T/lt unknown
- 2013-01-18 CN CN201380015401.8A patent/CN104507967B/zh not_active Expired - Fee Related
- 2013-01-18 HR HRP20181874TT patent/HRP20181874T1/hr unknown
- 2013-01-18 SG SG11201406762QA patent/SG11201406762QA/en unknown
- 2013-01-18 KR KR1020147023225A patent/KR102073034B1/ko not_active Expired - Fee Related
- 2013-01-18 ES ES13702548T patent/ES2698606T3/es active Active
- 2013-01-18 JP JP2014553482A patent/JP6352812B6/ja not_active Expired - Fee Related
- 2013-01-18 SG SG10201700735PA patent/SG10201700735PA/en unknown
- 2013-01-18 CA CA2862222A patent/CA2862222A1/en not_active Abandoned
- 2013-01-18 HU HUE13702548A patent/HUE041900T2/hu unknown
- 2013-01-18 US US13/745,377 patent/US8865870B2/en not_active Expired - Fee Related
- 2013-01-18 AU AU2013209492A patent/AU2013209492B2/en not_active Ceased
- 2013-01-18 BR BR112014017814A patent/BR112014017814A8/pt not_active Application Discontinuation
- 2013-01-18 PT PT13702548T patent/PT2804878T/pt unknown
- 2013-01-18 EP EP13702548.2A patent/EP2804878B1/en active Active
- 2013-01-18 RS RS20181422A patent/RS58141B1/sr unknown
- 2013-01-18 KR KR1020207002561A patent/KR20200014441A/ko not_active Ceased
- 2013-01-18 MX MX2014008728A patent/MX359854B/es active IP Right Grant
- 2013-01-18 WO PCT/US2013/022280 patent/WO2013109974A2/en not_active Ceased
- 2013-01-21 UY UY0001034582A patent/UY34582A/es not_active Application Discontinuation
- 2013-01-21 TW TW102102282A patent/TWI596112B/zh not_active IP Right Cessation
- 2013-01-21 AR ARP130100184A patent/AR090056A1/es unknown
-
2014
- 2014-07-17 IL IL233694A patent/IL233694A0/en unknown
- 2014-09-08 US US14/480,052 patent/US9765144B2/en not_active Expired - Fee Related
-
2017
- 2017-08-04 US US15/669,556 patent/US20180086838A1/en not_active Abandoned
-
2018
- 2018-05-07 JP JP2018089004A patent/JP6646100B2/ja not_active Expired - Fee Related
- 2018-09-14 US US16/132,333 patent/US20190119391A1/en not_active Abandoned
- 2018-11-22 CY CY20181101236T patent/CY1121335T1/el unknown
-
2019
- 2019-12-24 IL IL271697A patent/IL271697A/en unknown
-
2020
- 2020-01-08 JP JP2020001152A patent/JP2020072715A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506945A5 (enExample) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| CN105849124B (zh) | 双重特异性抗体 | |
| CN109715206B (zh) | 结合蛋白及其使用方法 | |
| CN101589062B (zh) | 与胰高血糖素受体抗体相关的组合物和方法 | |
| JP2022513420A5 (enExample) | ||
| JP7339948B2 (ja) | モノクローナル抗体およびその使用法 | |
| RU2014134043A (ru) | Анти-cxcr3 антитела | |
| JP7656330B2 (ja) | Ｃｄ４４に特異的な抗体 | |
| WO2017049452A1 (zh) | 抗人cd137的完全人抗体及其应用 | |
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| TW201838648A (zh) | 使用ｇｌｐ－１受體促效劑與抑胃肽受體（ｇｉｐｒ）結合蛋白之偶聯物治療或改善代謝病症之方法 | |
| CA2733432A1 (en) | Treatment of autoimmune and inflammatory disease | |
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| US20220372161A1 (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
| CN108517010A (zh) | 识别α-突触核蛋白的人源化抗体 | |
| WO2019137397A1 (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| CN114667296B (zh) | 一种双特异性抗体及其用途 | |
| JP7578289B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| WO2022143552A1 (zh) | Pd-1结合分子及其应用 | |
| EP3694879A1 (en) | Antibodies targeting pdl1 and methods of use thereof | |
| HK1254295A1 (zh) | 用於治疗纤维化和/或纤维化病症的抗-αＶ整合素抗体 | |
| EP3902836B1 (en) | Flt3 agonist antibodies and uses thereof | |
| TW202124432A (zh) | 使用pd-1軸抑制劑及抗骨膜蛋白抗體治療癌症之方法 | |
| WO2023125289A1 (zh) | 抗pd-1抗体及其用途 |